Vault RNA1 regulation of apoptosis in multidrug-resistant GLC4 small cell lung cancer cells by Teye, Emmanuel K.
  
 
ABSTRACT 
 
THESIS:  Vault RNA1 regulation of apoptosis in multidrug-resistant GLC4 small 
cell lung cancer cells 
STUDENT:  Emmanuel Kwame Teye 
DEGREE:  Master of Science 
COLLEGE:  Science and Humanities 
DEPARTMENT:  Biology 
DATE:  July, 2011 
PAGES:  123 
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that 
frequently develops multidrug resistance (MDR) during chemotherapy.  Vault RNA1 
(vRNA1), a non-structural component of the MDR-associated vault organelle, is 
believed to act as a microRNA (miRNA) and may contribute to MDR by regulating 
the expression of genes involved in apoptosis, inflammation, and/or drug metabolism.  
Since vaults function to aid cells in survival, we hypothesized that vRNA1 might be 
free in the cytoplasm and able to inhibit expression of pro-survival mRNAs when 
vaults are open in drug-sensitive GLC4/S cells but not in the MDR GLC4/ADR cells 
where vaults might be closed with the miRNA sequestered within.  In order to 
establish the role of vRNA1 as a regulator of survival in SCLC cells, siRNA-mediated 
down-regulation of vRNA1 was employed in GLC4/S and GLC4/ADR SCLC cells.  
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Fluorescence microscopy using a green fluorescent 3’ AlexaFluor-488 negative 
siRNA control was used to estimate transfection efficiency, yielding 56% for GLC4/S 
and 89% for GLC4/ADR. However, these values and the level of apoptosis before and 
after transfection, as judged by trypan blue hemacytometer cell counts, were not 
entirely reliable due to cell clumping.  The latter counts indicated a 2-fold decrease in 
viability in GLC4/S cell following transfection but no decrease in GLC4/ADR cells 
(p< 0.05). RT-PCR revealed that transfection significantly (p<0.05) decreased vRNA1 
expression in GLC4/S cells but not in GLC4/ADR cells, confirming our hypothesis 
concerning the availability of vRNA1 in the two cell types.  Caspase activity 
measurements showed vRNA1 down-regulation in the GLC4/ADR cells significantly 
(p≤0.05) increased survival via a 6.1-fold reduction in caspase 3/7 activity, further 
supporting our hypothesis.  However, GLC4/S cells showed a similar loss of 
apoptosis when transfected with either sivRNA1 or the negative control siRNA.   
vRNA1 down-regulation did not significantly (p≤0.05) affect the expression of major 
pro-survival (Bcl-2, Bcl-xL), pro-apoptotic (Bad), or pro-inflammatory (IL-6, NFĸB 
p65) factors in either GLC4/S or GLC4/ADR cells.  However, the drug metabolism 
protein CYP3A (previously shown by Persson et al., 2009 to be regulated by vRNA1) 
was significantly (p≤0.05) lowered (~16%) following vRNA1 down-regulation in the 
GLC4/S cells.   In conclusion, we were successful in down-regulating vRNA1 which 
enhanced cell survival as hypothesized, but we were not able to identify new proteins 
regulated by vRNA1. 
